
## R Jayachandra Babu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7342071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Difluprednate-Hydroxypropyl-β-Cyclodextrin-Based Ophthalmic Solution for Improved Delivery in a Porcine Eye Model. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 92-101.	1.4	2
2	Niosomal formulation of hydroxytyrosol, a polyphenolic antioxidant, for enhancing transdermal delivery across human cadaver skin. Pharmaceutical Development and Technology, 2022, , 1-9.	2.4	1
3	Recent Advancements of Stimuli-Responsive Targeted Liposomal Formulations for Cancer Drug Delivery. Pharmaceutical Nanotechnology, 2022, 10, 3-23.	1.5	4
4	pH-Sensitive Liposomes for Enhanced Cellular Uptake and Cytotoxicity of Daunorubicin in Melanoma (B16-BL6) Cell Lines. Pharmaceutics, 2022, 14, 1128.	4.5	11
5	Delignified wood aerogels as scaffolds coated with an oriented chitosan–cyclodextrin co-polymer for removal of microcystin-LR. RSC Advances, 2022, 12, 20330-20339.	3.6	4
6	Recent Advances in Lipid-Based Nanovesicular Delivery Systems for Melanoma Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 2021, 38, 1-38.	2.2	7
7	Resveratrolâ€loaded nanomedicines for cancer applications. Cancer Reports, 2021, 4, e1353.	1.4	74
8	Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities. Pharmaceutics, 2021, 13, 960.	4.5	25
9	Stabilityâ€indicating HPLC method for acyclovir and lidocaine in topical formulations. Biomedical Chromatography, 2020, 34, e4751.	1.7	15
10	Application of Extrusion-Based 3D Printed Dosage Forms in the Treatment of Chronic Diseases. Journal of Pharmaceutical Sciences, 2020, 109, 3551-3568.	3.3	29
11	Evaluation of Cytotoxicity and Taste-Masking Effect of Selected Flavors on Dental Lidocaine HCl Injection. Pharmaceuticals, 2020, 13, 353.	3.8	2
12	Co-Delivery of Hispolon and Doxorubicin Liposomes Improves Efficacy Against Melanoma Cells. AAPS PharmSciTech, 2020, 21, 304.	3.3	15
13	Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Safety, 2020, 43, 711-725.	3.2	37
14	Elucidating the anti-melanoma effect and mechanisms of Hispolon. Life Sciences, 2020, 256, 117702.	4.3	10
15	Dexamethasone eluting 3D printed metal devices for bone injuries. Therapeutic Delivery, 2020, 11, 373-386.	2.2	10
16	Flavonoids as Multi-Target Compounds: A Special Emphasis on their Potential as Chemo-adjuvants in Cancer Therapy. Current Pharmaceutical Design, 2020, 26, 1712-1728.	1.9	8
17	Enhanced Bioavailability of Boswellic Acid by Piper longum: A Computational and Pharmacokinetic Study. Frontiers in Pharmacology, 2020, 11, 551911.	3.5	11
18	Role of Ceramides in Drug Delivery. AAPS PharmSciTech, 2019, 20, 287.	3.3	6

#	Article	IF	CITATIONS
19	Use of sorbitol as pharmaceutical excipient in the present day formulations – issues and challenges for drug absorption and bioavailability. Drug Development and Industrial Pharmacy, 2019, 45, 1421-1429.	2.0	19
20	Co-delivery of Doxorubicin and Ceramide in a Liposomal Formulation Enhances Cytotoxicity in Murine B16BL6 Melanoma Cell Lines. AAPS PharmSciTech, 2019, 20, 99.	3.3	27
21	Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clinical Pharmacokinetics, 2018, 57, 1385-1398.	3.5	51
22	Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems. Journal of Pharmaceutical Sciences, 2018, 107, 1741-1753.	3.3	117
23	Pharmacokinetic evaluation of novel midazolam gel formulations following buccal administration to healthy dogs. American Journal of Veterinary Research, 2018, 79, 73-82.	0.6	6
24	Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus. Xenobiotica, 2018, 48, 89-108.	1.1	49
25	Non-alcoholic Steatohepatitis (NASH) Drug Discovery – Building a Consensus on ADME Screening Tools and Clinical Pharmacology Strategies to Aid Candidate Development. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 481-495.	2.1	2
26	In Situ Gel Formulation for Enhanced Ocular Delivery of Nepafenac. Journal of Pharmaceutical Sciences, 2018, 107, 3089-3097.	3.3	40
27	Improved Ocular Delivery of Nepafenac by Cyclodextrin Complexation. AAPS PharmSciTech, 2018, 19, 2554-2563.	3.3	18
28	Evaluation of non-crystalline cellulose as a novel excipient in solid dose products. Drug Development and Industrial Pharmacy, 2018, 44, 1512-1519.	2.0	3
29	Microemulsion and Microporation Effects on the Genistein Permeation Across Dermatomed Human Skin. AAPS PharmSciTech, 2018, 19, 3481-3489.	3.3	15
30	Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infectious Diseases, 2017, 49, 483-492.	2.8	24
31	Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 915-933.	1.6	59
32	Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences, 2017, 106, 1814-1820.	3.3	8
33	Comparative pharmacokinetics of three SCLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica, 2017, 47, 1015-1026.	1.1	18
34	The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer. Frontiers in Pharmacology, 2017, 8, 267.	3.5	23
35	Development of a Sustained-Release Voriconazole-Containing Thermogel for Subconjunctival Injection in Horses. , 2017, 58, 2746.		20
36	Implication of Formulation Strategies on the Bioavailability of Selected Plant-Derived Hepatoprotectants. Critical Reviews in Therapeutic Drug Carrier Systems, 2017, 34, 489-526.	2.2	4

#	Article	IF	CITATIONS
37	Percutaneous delivery of <b>α</b> -melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis. Journal of Drug Targeting, 2016, 24, 537-547.	4.4	12
38	Pyrrolidones as Penetration Enhancers. , 2015, , 291-299.		3
39	Stabilityâ€indicating HPLC assay for lysine–proline–valine (KPV) in aqueous solutions and skin homogenates. Biomedical Chromatography, 2015, 29, 716-721.	1.7	2
40	Progress in Topical siRNA Delivery Approaches for Skin Disorders. Current Pharmaceutical Design, 2015, 21, 4594-4605.	1.9	16
41	Lipid Materials for Topical and Transdermal Delivery of Nanoemulsions. Critical Reviews in Therapeutic Drug Carrier Systems, 2014, 31, 429-458.	2.2	36
42	Nanomedicine Scale-up Technologies: Feasibilities and Challenges. AAPS PharmSciTech, 2014, 15, 1527-1534.	3.3	221
43	Effect of Lipophilicity on Microneedle-Mediated Iontophoretic Transdermal Delivery Across Human Skin In Vitro. Journal of Pharmaceutical Sciences, 2013, 102, 3784-3791.	3.3	12
44	Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles. International Journal of Nanomedicine, 2013, 8, 137.	6.7	14
45	Microneedle assisted iontophoretic transdermal delivery of prochlorperazine edisylate. Drug Development and Industrial Pharmacy, 2012, 38, 571-576.	2.0	20
46	Amorphous-State Characterization of Efavirenz—Polymer Hot-Melt Extrusion Systems for Dissolution Enhancement. Journal of Pharmaceutical Sciences, 2012, 101, 3456-3464.	3.3	103
47	<i>In vitro</i> percutaneous absorption of genistein from topical gels through human skin. Drug Development and Industrial Pharmacy, 2011, 37, 498-505.	2.0	24
48	Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. Journal of Drug Targeting, 2011, 19, 731-740.	4.4	22
49	Encapsulation of hydrophobic drugs in a copolymer: Glass transition behavior and miscibility evaluation. Polymer Engineering and Science, 2011, 51, 1456-1465.	3.1	10
50	Single-Step Preparation and Deagglomeration of Itraconazole Microflakes by Supercritical Antisolvent Method for Dissolution Enhancement. Journal of Pharmaceutical Sciences, 2011, 100, 2952-2965.	3.3	20
51	Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. European Journal of Pharmaceutical Sciences, 2010, 39, 164-174.	4.0	32
52	Biphasic flux profiles of melatonin: The Yin–Yang of transdermal permeation enhancement mediated by fatty alcohol enhancers**"Yin―and "Yang―describe opposing qualities in a phenomenon, which are in a dynamic equilibrium. Each advance (Yang) is followed by a retreat (Yin), and every fall (Yin) transforms into a rise (Yang). Any mutable phenomenon is a consequence of Yin and Yang. Journal of	3.3	4
53	Pharmaceutical Sciences, 2010, 99, 209-218. Transdermal iontophoretic delivery of selegiline hydrochloride, <i>in vitro</i> . Journal of Drug Targeting, 2010, 18, 657-664.	4.4	11
54	Formulation of Controlled Release Gellan Gum Macro Beads of Amoxicillin. Current Drug Delivery, 2010, 7, 36-43.	1.6	99

R Jayachandra Babu

#	Article	IF	CITATIONS
55	Evaluation of EpiDerm full thickness-300 (EFT-300) as an in vitro model for skin irritation: Studies on aliphatic hydrocarbons. Toxicology in Vitro, 2010, 24, 669-676.	2.4	29
56	Polymeric and Lipid-Based Materials for Topical Nanoparticle Delivery Systems. Critical Reviews in Therapeutic Drug Carrier Systems, 2010, 27, 419-459.	2.2	25
57	Glass transitions in binary drug+polymer systems. Materials Letters, 2009, 63, 2666-2668.	2.6	23
58	Enhancement of transdermal delivery of phenylbutazone from liposomal gel formulations through deer skin. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 388-392.	1.3	6
59	Physicochemical Characterization of Efavirenz–Cyclodextrin Inclusion Complexes. AAPS PharmSciTech, 2009, 10, 81-87.	3.3	83
60	Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. Toxicology Letters, 2009, 185, 168-174.	0.8	11
61	Gefitinib–cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Development and Industrial Pharmacy, 2009, 35, 1113-1120.	2.0	37
62	Effect of Cyclodextrins on the Complexation and Nasal Permeation of Melatonin. Drug Delivery, 2008, 15, 381-388.	5.7	39
63	Cardiovascular effects of transdermally delivered bupranolol in rabbits: Effect of chemical penetration enhancers. Life Sciences, 2008, 82, 273-278.	4.3	8
64	Effect of dopaminergic neurotoxin MPTP/MPP+ on coenzyme Q content. Life Sciences, 2008, 83, 92-95.	4.3	7
65	Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. Toxicology, 2007, 237, 77-88.	4.2	26
66	In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDermâ,,¢ (EPI-200) cultured human skin and hairless rats. Toxicology Letters, 2006, 167, 85-94.	0.8	27
67	Stability and degradation profiles of Spantide II in aqueous solutions. European Journal of Pharmaceutical Sciences, 2006, 27, 158-166.	4.0	8
68	Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. International Journal of Pharmaceutics, 2005, 288, 325-334.	5.2	48
69	In vitro and in vivo evaluation of topical formulations of Spantide II. AAPS PharmSciTech, 2005, 6, E565-E572.	3.3	53
70	Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: Characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension. AAPS PharmSciTech, 2005, 6, E573-E585.	3.3	43
71	The effect of occlusive and unocclusive exposure to xylene and benzene on skin irritation and molecular responses in hairless rats. Archives of Toxicology, 2005, 79, 294-301.	4.2	11
72	Effect of methyl substitution of benzene on the percutaneous absorption and skin irritation in hairless rats. Toxicology Letters, 2005, 159, 261-271.	0.8	27

R Jayachandra Babu

#	Article	IF	CITATIONS
73	Effect of Penetration Enhancers on the Transdermal Delivery of Bupranolol Through Rat Skin. Drug Delivery, 2005, 12, 165-169.	5.7	28
74	Percutaneous absorption and skin irritation upon low-level prolonged dermal exposure to nonane, dodecane and tetradecane in hairless rats. Toxicology and Industrial Health, 2004, 20, 109-118.	1.4	25
75	Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist: Spantide II. Pharmaceutical Research, 2004, 21, 108-113.	3.5	23
76	Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin. International Journal of Pharmaceutics, 2004, 271, 155-165.	5.2	67
77	Assessment of skin irritation and molecular responses in rat skin exposed to nonane, dodecane and tetradecane. Toxicology Letters, 2004, 153, 255-266.	0.8	29
78	The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. Journal of Controlled Release, 2003, 86, 49-57.	9.9	44
79	Effect of Aging on the Dissolution Stability of Glibenclamide/β-Cyclodextrin Complex. Drug Development and Industrial Pharmacy, 1999, 25, 1215-1219.	2.0	13